EUVIMEDEUVIMED entdecken
Open Access

Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment

Advaitha Midde, Navpreet Arri, Tibor Kristian, Suprabhat Mukherjee, Parth Sarthi Sen Gupta, Yuji Zhang, Mariuz Karbowski, Jaylyn Waddell, Nagarajan Maharajan, Md Sazzad Hassan, Heather M O'Hagan, Michal Zalzman und 1 weitere

Cancer Letters · 2025

DOI: 10.1016/j.canlet.2025.217647 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Letters, 2025. Verfasst von Advaitha Midde und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of Maryland School of Medicine (UMSOM), Baltimore, MD, USA. Hauptthemen laut MEDLINE: Ribosomal Proteins, Melatonin, Diterpenes, Colonic Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDCD NIH HHS, NINDS NIH HHS, BLRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Colospheroids contain colon cancer stem cells (CSCs) that cause colorectal cancer metastasis (mCRC). Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in the U.S. Little is known about the role of mitochondria in the survival and metastatic ability of CSCs. In this study, we investigate the effect of andrographolide (AGP) and melatonin (MLT) on mitochondrial dynamics (including fusion and fission) and the expression of mitochondrial ribosomal proteins (MRPs). Our results show that AGP and MLT synergistically reduce the total active mitochondrial mass, downregulate fusion and fission proteins, reduce OXPHOS proteins, and lead to CSC growth inhibition via Nrf2 and KEAP1 signaling. Microarray revealed 4389 differentially expressed mRNAs in the AGP and MLT combination compared to the control. Results exhibiting a three-fold induction/reduction were validated by qRT-PCR and immunoblot. MRPS6, a mitochondrial ribosomal (Mitoribosome) small subunit protein, was dramatically downregulated by AGP + MLT treatment compared to control. MRPS6 inhibition by siRNA reduced mCRC cell viability. Molecular docking-based protein-ligand interactions showed that AGP has direct physical interaction with MRPS6 and increases the binding affinity of MLT to MRPS6. This drug combination downregulated genes in the NRF2 (NFE2L2) pathway in CSCs. MRPS6 may be directly linked to CSC proliferation and could be a therapeutic target for this population. Functionally, MRPS6 knockdown significantly reduced colony formation, with enhanced suppression in AGP + MLT-treated cells. In xenograft models, the AGP-MLT combination synergistically decreased MRPS6 expression and increased apoptosis, as evidenced by TUNEL assays, demonstrating the therapeutic potential of targeting MRPS6 in CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ribosomal ProteinsMelatoninDiterpenesColonic NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsMitochondrial ProteinsHumansAnimalsMitochondriaXenograft Model Antitumor AssaysCell Line, TumorNeoplastic Stem CellsGene Expression Regulation, NeoplasticMice, NudeMiceNF-E2-Related Factor 2Mitochondrial DynamicsCell ProliferationKelch-Like ECH-Associated Protein 1Cell SurvivalSignal Transduction

Stichwörter der Autor:innen

AndrographolideColon cancer stem cellsColospheroids (3D spheroids culture model)Fusion-fission proteinMelatoninMitochondrial dynamicsMitochondrial massMitochondrial ribosomal protein

Substanzen

Ribosomal ProteinsMelatoninandrographolideDiterpenesNFE2L2 protein, humanNF-E2-Related Factor 2Mitochondrial ProteinsKEAP1 protein, humanKelch-Like ECH-Associated Protein 1

Autor:innen und Institutionen

  • Department of Pediatrics, University of Maryland School of Medicine (UMSOM), Baltimore, MD, USA.
  • VAMHCS, UMSOM, Baltimore, MD, USA; Department of Anesthesiology and the Center for Shock, Trauma, and Anesthesiology Research (STAR), UMSOM, Baltimore, MD, USA.
  • Integrative Biochemistry & Immunology Laboratory(IBIL), Department of Animal Science, Kazi Nazrul University, Asansol, India.
  • School of Biosciences and Bioengineering, DY Patil International University, Pune, India.
  • Division of Biostatistics and Bioinformatics, Department of Epidemiology and Public Health, UMSOM, Baltimore, MD, USA.
  • Department of Biochemistry and Molecular Biology, UMSOM, Baltimore, MD, USA.

Förderung

  • NIDCD NIH HHS
  • NINDS NIH HHS
  • BLRD VA
  • National Institute of Neurological Disorders and Stroke
  • U.S. Department of Veterans Affairs
  • NIH
  • University of Maryland Baltimore School of Medicine

Zitieren

APA

Midde, A., Arri, N., Kristian, T., Mukherjee, S., Sen Gupta, P. S., Zhang, Y., Karbowski, M., Waddell, J., Maharajan, N., Hassan, M. S., O'Hagan, H. M., Zalzman, M., & Banerjee, A. (2025). Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment. Cancer Letters. https://doi.org/10.1016/j.canlet.2025.217647

Vancouver

Midde A, Arri N, Kristian T, Mukherjee S, Sen Gupta PS, Zhang Y, et al. Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment. Cancer Letters. 2025. doi:10.1016/j.canlet.2025.217647

BibTeX
@article{Midde2025,
  author = {Midde, Advaitha and Arri, Navpreet and Kristian, Tibor and Mukherjee, Suprabhat and Sen Gupta, Parth Sarthi and Zhang, Yuji and Karbowski, Mariuz and Waddell, Jaylyn and Maharajan, Nagarajan and Hassan, Md Sazzad and O'Hagan, Heather M and Zalzman, Michal and Banerjee, Aditi},
  title = {Targeting mitochondrial ribosomal protein expression by andrographolide and melatonin for colon cancer treatment},
  journal = {Cancer Letters},
  year = {2025},
  doi = {10.1016/j.canlet.2025.217647}
}
Kostenlos starten →